NCT01666691View on ClinicalTrials.gov

An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Obesity
Interventions
DRUG

Beloranib

Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.

DRUG

Placebo

Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.

Trial Locations (3)

5000

CMAX, Adelaide

6009

Linear Clinical Research Ltd, Perth

Unknown

Q-Pharm Clinics, Royal Brisbane and Women's Hospital, Brisbane

All Listed Sponsors
lead

Zafgen, Inc.

INDUSTRY

NCT01666691 - An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects | Biotech Hunter | Biotech Hunter